Clinical Trial TitleA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus
National Clinical Trial Number:NCT04294667
Clinical Trial Protocol Description:
The study will use an investigational new drug, Dapirolizumab Pegol (DZP), along with your existing systemic lupus erythematosus (SLE) medication. The purpose of the study is determine if DZP is effective in improving SLE. Participation in this study will require visits every four weeks over the course of 56 weeks. Visits during the treatment period will consist of infusion of the study drug, a physical examination, monitoring your vital signs, and questionnaires.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are 16 years of age or older.
- Are already using typical Lupus medications such as the following:
- Prednisone, Cellcept (mycophenolate), azathioprine
- Have a weight between 88 and 352 lbs ( to160kg).
- Have received a diagnosis of SLE more than 6 months ago.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.
Clinical Trial Investigator
Clinical Trial Location
RUSH University Medical Center
1620 W Harrison St
Chicago, IL 60612